Bevacizumab-induced hypertension is a marker for improved outcomes in recurrent glioblastoma

the ONA take:

According to a new study published in the journal Cancer, researchers have found that bevacizumab-induced hypertension may be a predictive marker of improved outcomes in patients with recurrent glioblastoma who are treated with bevacizumab. For the study, researchers identified 82 patients who received bevacizumab for the treatment of recurrent glioblastoma and classified them as normotensive or hypertensive depending on whether treatment-associated hypertension developed. Results showed that of the 82 patients enrolled, 30 developed bevacizumab-related hypertension which developed in a median time of 21 days. The median progression-free survival was 2.5 months (95% CI: 1.6 - 3.0) and 6.7 months (95% CI: 4.6 - 10.0) for the normotensive and hypertensive groups, respectively (P < 0.001). In addition, the median overall survival times were 4.9 months (95% CI: 4.4 - 6.8) for the normotensive group and 11.7 months (95% CI: 9.0 - 20.5) for the hypertensive group (P < 0.001). The findings suggest that among patients with recurrent glioblastoma treated with bevacizumab, those who developed bevacizumab-induced hypertension had significantly better progression-free survival and overall survival compared with those who did not. Therefore, the authors conclude that bevacuzmab-induced hypertension may be a physiologic marker of improved outcomes in patients with recurrent glioblastoma.

Bevacizumab-induced hypertension is a marker for improved outcomes in recurrent glioblastoma
Bevacizumab-induced hypertension is a marker for improved outcomes in recurrent glioblastoma
According to the results of the present study, patients with recurrent glioblastoma (GBM) who developed bevacizumab-induced hypertension demonstrated significantly better progression-free survival (PFS) and overall survival (OS) compared with normotensive individuals. Bevacizumab-induced hypertension may be a physiologic marker of outcome in patients with recurrent GBM.
READ FULL ARTICLE From Mdlinx
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs